Literature DB >> 9234386

Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression.

W Yasui1, Y Akama, H Yokozaki, S Semba, Y Kudo, F Shimamoto, E Tahara.   

Abstract

The expression of p53-inducible cyclin-dependent kinase inhibitor, p21WAF1/CIP1 in non-neoplastic mucosa, adenoma and adenocarcinoma of the colorectum was examined by immunohistochemistry and western blotting and its relation with the expression of p53 protein was analyzed. Non-neoplastic epithelial cells at the surface area showing no proliferative activity expressed p21WAF1/CIP1. The expression of p21WAF1/CIP1 was immunohistochemically detected in 55% (206/377) of the adenomas and 66% (190/289) of the adenocarcinomas, respectively. The incidence of strongly positive cases was significantly higher in the adenocarcinomas (27%) than in the adenomas (18%) (P < 0.05). The incidence of cases with strong p21WAF1/CIP1 expression was higher in stages 0, 1 and 2 carcinomas than in stages 3 and 4 carcinomas (P < 0.05). A decrease in the incidence of cases with strong expression was detected in carcinomas invading deeper than muscularis propria. The incidence of strongly positive cases was significantly lower in carcinomas with lymph node metastasis than those without metastasis (P < 0.05). The expression of p21 as well as p53 detected by western blotting was compatible with the results of immunohistochemistry in most cases examined. However, there was no significant correlation between the expression of p21WAF1/CIP1 and the abnormal accumulation of p53. These findings overall suggest that: (i) the physiological expression of p21WAF1/CIP1 may be associated with cellular senescence of colorectal mucosa; (ii) reduced expression of p21WAF1/CIP1 may participate in the progression of colorectal carcinoma; and (iii) p53-independent pathway may be considerably involved in the induction of p21WAF1/CIP1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234386     DOI: 10.1111/j.1440-1827.1997.tb04526.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

Review 1.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

2.  Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression.

Authors:  S Siavoshian; J P Segain; M Kornprobst; C Bonnet; C Cherbut; J P Galmiche; H M Blottière
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

3.  Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas.

Authors:  Tomonori Sasahira; Yoshihiko Akama; Kiyomu Fujii; Hiroki Kuniyasu
Journal:  Virchows Arch       Date:  2005-03-24       Impact factor: 4.064

4.  Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features.

Authors:  Elli E Ioachim; Konstantinos H Katsanos; Michael C Michael; Epameinondas V Tsianos; Niki J Agnantis
Journal:  Int J Colorectal Dis       Date:  2004-04-02       Impact factor: 2.571

5.  Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.

Authors:  S Aaltomaa; P Lipponen; M Ala-Opas; M Eskelinen; K Syrjänen; V M Kosma
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

6.  p22/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis.

Authors:  K M Ropponen; J K Kellokoski; P K Lipponen; T Pietiläinen; M J Eskelinen; E M Alhava; V M Kosma
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.